Abstract
Between 1987 and 2000, the German mesothelioma register recorded a total of 4,455 patients with malignant mesotheliomas. Survival times for 498 (11.2%) patients were available; 155 patients (study group, 3.5% of the total group) survived for more than 2 years and 343 patients (control group, 7.7% of the total group) survived for fewer than 24 months. Male patients were over-represented in both groups, with 13% of women in the study and 4.4% in the control group. The proportion of pleural mesotheliomas was more than 90% in both groups, with peritoneal cases comprising 6.5% in the study group and 3.2% in the control group. Histologically, the epithelioid subtype was represented in 58% of the study group, whereas the biphasic subtype predominated (67.6%) in the control group. Only 7% of tumours were of the sarcomatoid subtype. The average age of patients in the study group was 57.4 years, thus lower than in the control group (62.8 years). Lung dust analysis showed an increased pulmonary asbestos burden in 94% of all patients; significant differences between the study and control group were not observed. In the majority of the total group pleural effusions were the first symptoms. Therapeutic data were available in fewer than 40% of all cases. Surgical interventions were performed, partly in combination with radiation and chemotherapy and as alternative treatments. Significant deviations in survival time dependent on therapy applied could not be proved. By multivariate analysis (Cox proportional hazards regression model) favourable prognostic factors for long-term survival were epithelioid tumour subtype, comparatively young age (<60 years), and female gender (P<0.05).
Similar content being viewed by others
References
Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernazt PE (1986) Diffuse malignant mesothelioma of the pleura. Diagnosis and survival in 92 cases. Cancer 58:1540–1551
Agudo A Gonzales C, Bleda M, Ramirez J, Hernandez S, Lopez F, Calleja A, Panades R, Turuguet D, Escolar A, Beltran M, Gonzales-Moya JE (2000) Occupation and risk of malignant pleural mesothelioma. A case control study in Spain. Am J Ind Med 37:159–168
Antmann KH (1993) Natural history and epidemiology of malignant mesothelioma. Chest 103[Supp]:373S–76S
Antmann KH, Shemin R, Ryan L (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana Farber Institute and Brigham and Woman’s Hospital experience over two decades J Clin Oncol 6:147–153
Attanoos R, Gibbs AR (1998) Peritoneal mesothelioma: clinicopathological analysis of 227 cases from the UK mesothelioma register. Clin Exp Pathol 46:376–376
Baas P (2002) Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 29:62–69
Beer TW, Buchanan R, Mathews AW, Stradling R, Pullinger N, Pethybridge RJ (1998) Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype. Hum Pathol 29:246–251
Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1999) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40:1241–1245
Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C (1997) Latency periods in asbestos related mesothelioma of the pleura. Eur J Cancer Prev 6:162–166
Bischoff HG, Manegold C, Drings P (2000) Langzeit-Spontanverlauf beim malignen Pleuramesotheliom. Pneumologie 54:S31
Blecklake MR (1976) Asbestos related diseases of the lung and other organs: their epidemiology and implications for clinical practice. Am J Respir Dis 114:187–227
Brenner J, Sordillo PP, Magill MG, Golbey RB (1981) Malignant peritoneal mesothelioma: review of 25 patients. Am J Gastroenterol 75:311–313
Brenner J, Sordillo PP, Magil GB, Golgey RB (1982) Malignant mesothelioma of the pleura. Cancer 49:2431–2435
Brockmann M, Fischer M, Müller KM (1989) Lungenstaubanalyse bei Bronchialkarzinomen. Atemw Lungenkrkh 15:263–265
Browne K, Smither WJ (1983) Asbestos related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 40:145–152
Chahinian APH, Pajak TF, Holland JF, Norton L, Armbinder RM, Mandel EM (1982) Diffuse malignant mesothelioma (prospective evaluation of 69 patients) Ann Intern Med 96:746–755
Chailleux E, Dabouis G, Pioche D, deLajarte M, deLajarte AY, Rembeaux A, Germaud P (1988) Prognostic factors in diffuse malignant pleural mesothelioma. Chest 93:159–162
Craighead JE (1982) Asbestos related diseases. Arch Pathol Lab Med 106:544–596
Dienemman H, Trainer C (2000) Mesotheliom der Pleura und des Peritoneums. Chirurg 71:887–893
Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognosis scoring systems. Thorax 55:731–735
Ehlers EM, Kühnel W, Wiedemann GJ (2002) Hyperthermia and mafosfamide in a human derived malignant pleural mesothelioma cell line. J Cancer Res Clin Oncol 128:65–72
Elmes PC, Simpson JC (1976) The clinical aspects of mesothelioma. Q J Med 45:427–449
Fizazi K, John WJ, Vogelzang NJ (2002) The emerging role of antifolates in the treatment of malignant mesothelioma. Semin Oncol 1:77–81
Frizelle SP, Rubins JB, Zhou JX (2000) Gene therapy of established mesothelioma xenograft with recombinant p16INK4a adenovirus. Cancer Gene Ther 7:1421–1425
Girling DJ, Muers MF, Qian W, Lobban D (2002) Multicentre randomised controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society Medical Research Council. Semin Oncol 29:97–101
Grondin C, Sugarbaker DJ (1999) Malignant mesothelioma of the pleural space. Oncology 13:919–26
Hillerdal G (1983) Malignant mesothelioma. Review of 4710 published cases. Br J Dis Chest 77:321–343
Howel D, Arblaster L, Swinburne L, Schweiger M, Renvoize E, Hatton P (1997) Routes of asbestos exposure and the development of mesothelioma in an English region. Occup Environ Med 54:403–409
Jaklitsch MT Grondin SC, Sugarbaker DJ (2001) Treatment of malignant mesothelioma. World J Surg 25:210–217
Kjaergaard J, Andersson M (2000) Incidence rates of malignant mesothelioma in Denmark predicted future number of cases among men. Scand J Work Environ Health 26:112–117
Kramer G, Gans S, Rijnders A, Leer JW (2000) Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease with90yttrium-silicate. Lung Cancer 27:205–208
Kucharczuk JC, Kaiser LR (1997) Use of a replication restricted herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57:466–471
Lanphear BP, Buncher RC (1992) Latent period for malignant mesothelioma of occupational origin. J Occup Med 34:718
Livitra EJ, Vyas V, Nelson K, Musanti R, Beers St, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, Aisner J, Gounder M, Rajendra R, Saleem A, Toppmeyer D, Rubin EH (2003) Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res 9:1673–1679
McDonald AD, McDonald JC (1980) Malignant mesothelioma in North America. Cancer 46:1650–1656
Middleton GW, Smith IE, O’Brian MER (1998) Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9:269–273
Müller KM (1997) Mesotheliome: Pathologie/Pathogenese/Mesotheliomregister. Pneumologie 51:335–344
Neumann V, Müller KM, Fischer M (1999) Peritoneale Mesotheliome—Häufigkeiten und Ätiologie. Pathologe 20:169–176
Neumann V, Günther S, Müller KM, Fischer M (2001) Malignant mesothelioma—German mesothelioma register 1987 to 1999. Int Arch Occup Environ Health 74:383–395
Ng DC, Hain SF, O’Doherty MJ, Dussek J (2000) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 41:1443–1444
Otto H (1980) Das berufsbedingte Mesotheliom in der BRD. Pathologe 2:8–18
Peto J, Decarli A, LaVecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672
Rieck G, Neumann V, Müller KM, Fischer M (2002) Lange Überlebenszeiten bei Patienten mit malignen Mesotheliomen—Gibt es einen Bezug zur histologischen Subtypisierung? Atemw Lungenkrkh 28:371–372
Robinson B (2002) Biology and gene therapy of malignant mesothelioma. Second Heidelberg thoracic oncology symposium: diagnosis and treatment of pleural mesothelioma in Heidelberg, limited handout, German Thoraxklinik, Heidelberg, Germany
Roggli VL, Oury TD, Moffatt EJ (1997) Malignant mesothelioma in women. In: Fechner RE, Rosen PP (eds) Anatomic pathology, vol 2. ASCP Press, pp 147–163
Ruffie P, Feld R, Minkin S (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec, a retroprospective study of 332 patients. J Clin Oncol 8:1157–1168
Rusch VW, Venkatraman E (1999) Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68:1799–1802
Ryan CW, Herndorn J, Vogelzang NJ (1998) A review of chemotherapy trials for malignant mesothelioma. Chest 113:66S–73S
Smythe WR (2002) Current therapy for malignant mesothelioma Curr Oncol Rep 4:305–313
Steele JPC, Shamasch J, Evans MT (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912–3917
Sterman DH, Treat J, Kaiser LR (1998) Adenovirus mediated herpes simplex virus thymidine kinase ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083–1092
Strizzi L, Muaro R, Vianale G, Natoli C, Talone L, Catalano A, Mutti L, Tassi G, Procopio A (2002) Expression of glycoprotein 90 k in human malignant mesothelioma: correlation with patient survival. J Pathol 197:218–223
Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp, Swanson MM, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–65
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzmeier U, Boyer M, Emri S, Manegold C, Niykiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 15:2636–2644
Wächli I, Rajower I, Christens B, Mirza S, Rüttner JR (1988) Ferruginous Bodies im Lungenstaub als Indikatoren für Asbestschäden. Pathologe 8:346–350
Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Brit J Ind Med 17:260–271
Warren WH (2000) Malignancies involving the pericardium. Semin Thorac Cardiovasc Surg 12:119–129
Woitowitz HJ, Grossgarten K (1991) Pleuramesotheliom: Ätiologie und praktische Konsequenzen. Pneumologie 45:153–158
Yates DH, Corrin B, Stidolph PN, Browne K (1997) Malignant mesothelioma in South East England: clinicopathological experience of 272 cases. Thorax 52:507–512
Zellos LS, Sugarbaker DJ (2002) Diffuse malignant mesothelioma of the pleural space and its management. Oncology 16:907–913
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neumann, V., Rütten, A., Scharmach, M. et al. Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register. Int Arch Occup Environ Health 77, 191–199 (2004). https://doi.org/10.1007/s00420-003-0498-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00420-003-0498-6